Pathological and Transcriptome Changes in the ReninAAV db/db uNx Model of Advanced Diabetic Kidney Disease Exhibit Features of Human Disease. (December 2018)

• Record Type: Journal Article
• Authors: Harlan, Shannon M.; Heinz-Taheny, Kathleen M.; Overstreet, Jessica M.; Breyer, Matthew D.; Harris, Raymond C.; Heuer, Josef G.
• Other Names: Heinz-Taheny Kathleen guest-editor.; Frazier Kendall guest-editor.; Ramaiah Shashi guest-editor.
• Is Part Of: Toxicologic pathology. Volume 46:Number 8(2018)
• Page Start: 991
• Page End: 998
• Publication Date: 2018-12
• Subjects: animal models -- mouse pathology -- renal -- diabetes; Pathology -- Periodicals; Toxicology -- Periodicals; Pathology; Toxicology; 615.9
• DOI: 10.1177/0192623318804986
• Languages: English
• ISSNs: 0192-6233

Abstract

The ReninAAV db/db uNx model of diabetic kidney disease (DKD) exhibits hallmarks of advanced human disease, including progressive elevations in albuminuria and serum creatinine, loss of glomerular filtration rate, and pathological changes. Microarray analysis of renal transcriptome changes were more similar to human DKD when compared to db/db eNOS −/− model. The model responds to treatment with arterial pressure lowering (lisinopril) or glycemic control (rosiglitazone) at early stages of disease. We hypothesized the ReninAAV db/db uNx model with advanced disease would have residual disease after treatment with lisinopril, rosiglitazone, or combination of both. To test this, ReninAAV db/db uNx mice with advanced disease were treated with lisinopril, rosiglitazone, or combination of both for 10 weeks. All treatment groups showed significant lowering of urinary albumin to creatinine ratio compared to baseline; however, only combination group exhibited lowering of serum creatinine. Treatment improved renal pathological scores compared to baseline values with residual disease evident in all treatment groups when compared to db/m controls. Gene expression analysis by TaqMan supported pathological changes with increased fibrotic and inflammatory markers. The results further validate this model of DKD in which residual disease is present when treated with agents to lower arterial pressure and glycemic control.